Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. H. Lundbeck A/S
  6. Summary
    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
10/15/2021 10/18/2021 10/19/2021 10/20/2021 10/21/2021 Date
175.55(c) 174.05(c) 175.65(c) 176.75(c) 175.2(c) Last
286 580 146 763 309 086 274 387 217 656 Volume
+1.18% -0.85% +0.92% +0.63% -0.88% Change
More quotes
Estimated financial data (e)
Sales 2021 16 435 M 2 568 M 2 568 M
Net income 2021 1 451 M 227 M 227 M
Net Debt 2021 2 164 M 338 M 338 M
P/E ratio 2021 24,1x
Yield 2021 1,62%
Sales 2022 17 613 M 2 752 M 2 752 M
Net income 2022 1 976 M 309 M 309 M
Net cash position 2022 133 M 20,8 M 20,8 M
P/E ratio 2022 18,0x
Yield 2022 2,29%
Capitalization 34 812 M 5 446 M 5 440 M
EV / Sales 2021 2,25x
EV / Sales 2022 1,97x
Nbr of Employees 5 603
Free-Float 30,7%
More Financials
Company
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression... 
Sector
Pharmaceuticals
Calendar
11/10Earnings Release
More about the company
Ratings of H. Lundbeck A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about H. LUNDBECK A/S
10/14H LUNDBECK A/S : Lundbeck Acquires Exclusive Rights To APB-A1 From AprilBio
MT
10/14H LUNDBECK A/S : Lundbeck receives exclusive rights to APB-A1, an innovative phase I-ready..
AQ
10/14Lundbeck Receives Exclusive Rights to APB-A1, an Innovative Phase I-Ready Bio Therapeut..
CI
10/14Lundbeck Receives Exclusive Rights to APB-A1, an Innovative Phase I-Ready Bio-Therapeut..
CI
10/13Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance of Supplem..
CI
10/04H LUNDBECK A/S : World Mental Health Day 2021
PU
10/04H. LUNDBECK A/S : - U.S. court issues decision in Trintellix patent litigation upholding a..
AQ
10/01H LUNDBECK A/S : U.S. court issues decision in Trintellix patent litigation upholding acti..
AQ
09/20H LUNDBECK A/S : A family portrait of the brain
PU
09/14HERANTIS PHARMA OYJ : Names Chairman of New Scientific Advisory Board
MT
08/18H LUNDBECK A/S : Drugmaker Lundbeck lowers sales outlook as generic competition bites
RE
08/18H LUNDBECK A/S : Lundbeck continues to deliver solid growth for strategic brands and the f..
AQ
08/18H. Lundbeck A/S Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/04H LUNDBECK A/S : Lundbeck enters strategic research collaboration with Rgenta Therapeutics..
PU
08/04Rgenta Therapeutics, Inc. Enters into a Collaboration with H. Lundbeck A/S
CI
More news
News in other languages on H. LUNDBECK A/S
10/14Lundbeck acquiert les droits exclusifs sur APB-A1 auprès d'AprilBio
05/12MSCI streicht Hochtief-Aktie aus Deutschland-Index
05/11Les valeurs à suivre à Paris et en Europe
05/06ÜBERBLICK/Anstehende Indexänderungen
04/13H. LUNDBECK A/S : coup d'arrêt
More news
Analyst Recommendations on H. LUNDBECK A/S
More recommendations
Chart H. LUNDBECK A/S
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | LUN | DK0010287234 | MarketScreener
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 175,20 DKK
Average target price 227,93 DKK
Spread / Average Target 30,1%
EPS Revisions
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders Götzsche Chief Financial Officer & Executive Vice President
Lars Søren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
H. LUNDBECK A/S-15.35%5 496
JOHNSON & JOHNSON4.07%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.14.34%239 966
NOVO NORDISK A/S56.26%238 738
ELI LILLY AND COMPANY44.35%220 952